CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...
Indiatimes16d
New hope for chronic hand eczema patients: Tofacitinib clinical trial shows 90% improvement
RML Hospital's clinical study reports that Tofacitinib shows a remarkable 90% improvement in chronic hand eczema symptoms for 12 of 15 patients within four weeks. The condition primarily affects ...
Medical Xpress21d
Upadacitinib found to improve ulcerative colitis outcomes at 12 months
For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December ...